+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Anorexia Nervosa Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 181 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 6015168
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Anorexia Nervosa Market grew from USD 121.83 million in 2025 to USD 144.71 million in 2026. It is expected to continue growing at a CAGR of 13.66%, reaching USD 298.60 million by 2032.

Comprehensive introduction to the multifaceted clinical, delivery, and policy environment shaping anorexia nervosa care and strategic priorities in modern practice

Anorexia nervosa remains one of the most complex and clinically consequential eating disorders, characterized by profound medical risk and persistent psychosocial impact. Over the past decade, advances in diagnostic frameworks, a growing evidence base for integrated treatment approaches, and evolving payer expectations have reshaped how clinicians, hospitals, and specialized programs conceive of recovery pathways. Clinicians increasingly emphasize early intervention, family-centered models for adolescent care, and coordinated rehabilitation strategies that address both physiological stabilization and long-term relapse prevention.

Concurrently, technology-enabled care modalities have expanded the reach of specialized providers while changing patient engagement patterns. Telehealth platforms have created new opportunities to deliver nutritional counseling and psychotherapy at scale, yet they also introduce considerations around safety monitoring and the management of acute medical risk. Moreover, workforce constraints and regional disparities in provider availability continue to shape service design, leading many systems to trial hybrid models that combine in-person stabilization with remote follow-up and interdisciplinary care coordination.

Given this backdrop, payers and health systems are focused on evidence-informed pathways that reduce rehospitalization, shorten crisis episodes, and support sustainable recovery. As stakeholders navigate these priorities, the discourse has shifted from isolated clinical interventions toward comprehensive systems of care that integrate medical, nutritional, and psychosocial supports, emphasizing measurable outcomes and continuity across transitions of care.

Critical transformative shifts in clinical practice models, digital adoption, reimbursement frameworks, and public health priorities that are redefining anorexia nervosa care delivery

The landscape of anorexia nervosa care is undergoing transformative shifts driven by clinical innovation, technology adoption, regulatory attention, and changing stakeholder expectations. Novel therapeutic frameworks are integrating nutritional rehabilitation with targeted psychotherapies and selective pharmacologic strategies, leading to more personalized treatment plans while emphasizing the importance of multidisciplinary teams. At the same time, digital therapeutics and telehealth have moved from supplemental options to essential components of care pathways, enabling continuity for patients in geographically underserved areas and facilitating stepped-care approaches that align intensity of service with clinical acuity.

Health systems and payers are redefining value by focusing on outcomes such as sustained weight restoration, reduced medical complications, and improved psychosocial functioning. This has catalyzed new reimbursement conversations around bundled care, hybrid care models, and performance-based contracting, prompting providers to adopt measurement frameworks that can demonstrate clinical effectiveness. Additionally, there is a growing emphasis on workforce development, including specialized training for clinicians in evidence-based therapies and protocols for safe remote monitoring.

Public health discourse has also evolved, with increased attention to adolescent mental health, early screening in primary care settings, and anti-stigma campaigns that encourage help-seeking. These shifts collectively are altering referral patterns, accelerating adoption of integrated care models, and prompting providers to rethink how services are packaged, delivered, and evaluated to achieve durable recovery outcomes.

Assessment of how United States tariff adjustments announced for 2025 can reverberate across supply chains, procurement choices, and service availability for anorexia nervosa care

Policy changes relating to tariffs and trade in 2025 exert multifaceted downstream effects on the clinical ecosystem supporting anorexia nervosa care, particularly through supply chain and procurement channels. Increased tariffs on imported medical equipment and diagnostic devices can raise acquisition costs for hospitals and specialized clinics, thereby influencing capital planning and the pace at which facilities upgrade monitoring technologies essential for safe medical stabilization. Similarly, tariffs applied to certain pharmaceutical imports or raw ingredients for therapeutics have implications for inventory management, formulary decisions, and the operational costs borne by treatment programs.

These cost pressures often propagate to smaller specialized clinics and residential programs more acutely, as their procurement volumes and negotiating power are typically more limited than larger hospital systems. In turn, programs may respond by extending equipment lifecycles, prioritizing essential purchases, or exploring alternative sourcing arrangements. Such adjustments can affect the availability and distribution of advanced monitoring devices and telehealth peripherals that facilitate remote clinical oversight.

Moreover, the indirect impact on supply chains may accentuate regional disparities in access to high-acuity care, as facilities in resource-constrained areas face longer procurement timelines and constrained budgets. Payers and providers must therefore consider strategies that mitigate supply risks, including regional procurement consortia, standardized clinical protocols that optimize existing resources, and targeted investments in technologies that offer long-term operational efficiencies. In this context, stakeholders should emphasize resilience in sourcing, while aligning purchasing decisions with clinical safety imperatives and long-term care quality objectives.

Granular segmentation insights that illuminate how treatment setting, therapeutic modality, provider type, and patient age interact to shape clinical pathways and service design for anorexia nervosa

Understanding anorexia nervosa through a segmentation lens clarifies how treatment pathways and service design vary by modality, therapeutic approach, end-user setting, and patient age cohort. Treatment settings range from structured, high-intensity inpatient hospitalization to residential treatment environments that provide sustained psychosocial support, and to day treatment programs that blend medical oversight with intensive outpatient therapies. Each setting carries distinct staffing models, monitoring protocols, and discharge-planning workflows that influence transitions of care and long-term outcomes.

Therapy modalities are similarly heterogeneous. Nutritional counseling remains foundational to restoration of health and is commonly integrated with psychotherapeutic interventions. Pharmacotherapy plays a complementary role for select clinical presentations, with atypical antipsychotics and selective serotonin reuptake inhibitors serving specific symptomatic or comorbid indications. Psychotherapy is a core pillar of treatment, encompassing evidence-based approaches such as cognitive behavioral therapy, family based therapy, and interpersonal therapy, each tailored to developmental stage and clinical presentation. The interplay between these modalities determines protocol sequencing, intensity of services, and measurement priorities.

End-user contexts shape service delivery and access. Hospitals are often the locus of medical stabilization and complex case management, specialized clinics deliver focused multidisciplinary care with expertise in eating disorders, and telehealth providers extend reach for ongoing counseling and follow-up. Finally, age-group considerations matter: clinical pathways and family engagement strategies differ markedly for adolescents compared with adults and children, affecting consent processes, school reintegration planning, and caregiver involvement. Taken together, these segmentation dimensions inform program design, workforce training needs, and outcome measurement frameworks.

Key regional intelligence outlining how the Americas, Europe Middle East and Africa, and Asia-Pacific each present distinct access, workforce, cultural, and policy considerations for anorexia treatment delivery

Regional dynamics materially influence how anorexia nervosa services are organized, resourced, and accessed across different health systems. In the Americas, concentrated centers of excellence coexist with significant geographic variation in service availability, prompting hybrid care models and telehealth expansions to bridge gaps between urban specialty programs and rural communities. Policy attention to adolescent mental health and integrated primary care screening has begun to reshape referral pathways, producing earlier detection in some jurisdictions and increasing demand for specialized outpatient programs.

Within Europe, the Middle East, and Africa, heterogeneity across health systems drives diverse priorities: some countries emphasize publicly funded multidisciplinary services and regulated residential care, while others rely on a mix of private providers and charity-funded programs. Workforce capacity and cultural considerations influence engagement strategies, family involvement, and community reintegration practices. Cross-border collaborations and academic networks frequently support clinical training and guideline dissemination, yet logistical and regulatory constraints can complicate multicenter research and standardized implementation.

The Asia-Pacific region presents both rapid innovation and disparity. Urban centers are increasingly adopting digital health solutions, novel service models, and specialized clinics, while many areas contend with limited specialist availability and variable awareness of eating disorders. Cultural factors shape help-seeking behaviors, stigma, and the acceptability of family-centered therapies. Across all regions, regulatory and reimbursement frameworks determine the pace of adoption for telehealth, digital therapeutics, and integrated care pathways, underscoring the need for context-sensitive strategies that address local system strengths and constraints.

Company and organizational dynamics that reveal how providers, technology vendors, and therapeutic developers can form alliances and capabilities to deliver integrated anorexia care with measurable outcomes

Company and organizational behavior in the anorexia nervosa care ecosystem reflect a combination of clinical specialization, technology-enabled innovation, and strategic partnerships. Providers that demonstrate strong integration between medical stabilization, nutritional expertise, and psychotherapeutic capacity tend to lead in outcomes-focused programs. Meanwhile, digital health entrants and telehealth platforms are expanding access and creating new pathways for longitudinal engagement, often partnering with specialist clinics to deliver stepped-care models that triage intensity according to clinical need.

Pharmaceutical manufacturers and therapeutic developers are focusing on adjunctive treatments that address comorbidities and symptom domains not fully remediated by psychotherapy and nutritional rehabilitation alone. Collaborations between clinical researchers, specialty programs, and industry partners have accelerated trial designs that evaluate adjunctive pharmacologic strategies within comprehensive care packages. At the same time, device manufacturers supplying monitoring equipment and telehealth peripherals are adapting to demand for remote vitals monitoring and enhanced safety features to support outpatient treatment of medically fragile patients.

Across the landscape, organizations that prioritize interoperable data systems, standardized outcome measures, and collaborative care models are better positioned to demonstrate value to payers and health systems. Strategic alliances-whether between hospital systems and specialty clinics, or between digital platforms and clinician networks-are emerging as a key route to scale services while preserving clinical fidelity. Leaders in this space invest in workforce training, quality improvement, and evidence generation to sustain competitive differentiation and to support multi-stakeholder alignment around care standards.

Actionable strategic recommendations for health systems, payers, and providers to optimize integrated care pathways, procurement resilience, reimbursement alignment, and outcome measurement for anorexia treatment

Industry leaders should prioritize integrated care pathways that explicitly connect medical stabilization, nutritional rehabilitation, and evidence-based psychotherapy while enabling continuity through digital tools. Establishing clear protocols for transition between inpatient, residential, day treatment, and outpatient settings reduces fragmentation and supports consistent outcome measurement. Investing in clinician training focused on family-based interventions and adolescent-specific approaches will strengthen early intervention capabilities and improve long-term prognosis.

Payers and providers should explore value-aligned contracting models that incentivize reduced rehospitalization and sustained functional recovery rather than discrete episode billing. To mitigate procurement and supply risks, organizations ought to evaluate regional sourcing consortia, standardized equipment specifications, and long-term vendor relationships that prioritize device reliability and remote monitoring capabilities. Embracing telehealth as a core delivery channel requires robust safety protocols, clinician competencies for remote assessment, and systems for escalation to higher-intensity care when necessary.

Finally, decision-makers should invest in interoperable outcomes registries and real-world evidence generation to demonstrate clinical effectiveness and inform continuous quality improvement. Partnerships across academic centers, specialty clinics, and technology firms can accelerate innovation while ensuring adherence to clinical best practices. By aligning reimbursement incentives, workforce development, and digital infrastructure with patient-centered care models, leaders can improve access and outcomes across diverse populations.

Transparent, multidisciplinary research methodology detailing evidence synthesis, stakeholder engagement, case-based pathway analysis, and iterative validation to ground practical insights

The research approach underpinning these insights combined a multi-source evidence synthesis with stakeholder engagement and qualitative validation to ensure robustness and relevance. Clinical literature and guideline reviews provided the foundational understanding of therapeutic efficacy and standard-of-care practices, while analysis of regulatory guidance and reimbursement frameworks informed the assessment of systemic constraints and enablers. Expert interviews with clinicians, program directors, and digital health leaders supplied frontline perspectives on care delivery, workforce issues, and operational challenges.

Complementing these inputs, case-based analyses of care pathways were conducted to illustrate successful models of integration across inpatient, residential, day treatment, and outpatient settings. Operational considerations such as procurement processes, equipment replacement cycles, and telehealth implementation strategies were triangulated using aggregated procurement and health system management sources. Ethical considerations, patient safety considerations, and standards for remote monitoring were central to methodological design, and all recommendations emphasize alignment with best-practice clinical governance.

Throughout the study, an iterative validation process ensured fidelity to real-world constraints by presenting preliminary findings to multidisciplinary advisors for critique and refinement. This approach balanced empirical evidence, practitioner experience, and system-level analysis to deliver actionable insights that are clinically grounded and operationally feasible.

Conclusive synthesis of clinical progress, systemic challenges, segmentation takeaways, and strategic priorities to guide executive decision-making in anorexia nervosa care

The contemporary care landscape for anorexia nervosa reflects significant progress in integrating medical, nutritional, and psychotherapeutic interventions, coupled with emergent opportunities from digital health and hybrid care models. Stakeholders face converging pressures-workforce limitations, procurement and supply chain dynamics, and evolving reimbursement expectations-that require coordinated strategies to preserve care quality and expand access. Segmentation by treatment setting, therapy type, provider context, and age group highlights the necessity of tailored pathways rather than one-size-fits-all solutions.

Regional variation underscores the importance of contextualized implementation, whether addressing capacity gaps in the Americas, harmonizing multidisciplinary services across Europe, the Middle East, and Africa, or scaling digital-first solutions in Asia-Pacific while addressing cultural and workforce constraints. Organizational leaders and manufacturers that pursue strategic partnerships, invest in interoperable outcomes measurement, and adopt resilient procurement practices will be better positioned to deliver sustainable, high-quality care.

In closing, the path forward is one of integration: aligning clinical standards, technology adoption, workforce training, and payment reform to support durable recovery trajectories. Policymakers, clinical leaders, and commercial stakeholders who act on these coordinated priorities can meaningfully improve outcomes for individuals affected by anorexia nervosa while ensuring systems remain responsive to changing clinical and economic conditions.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Anorexia Nervosa Market, by Treatment Type
8.1. Day Treatment Program
8.2. Inpatient Hospitalization
8.3. Residential Treatment
9. Anorexia Nervosa Market, by Therapy Type
9.1. Nutritional Counseling
9.2. Pharmacotherapy
9.2.1. Atypical Antipsychotics
9.2.2. Selective Serotonin Reuptake Inhibitors
9.3. Psychotherapy
9.3.1. Cognitive Behavioral Therapy
9.3.2. Family Based Therapy
9.3.3. Interpersonal Therapy
10. Anorexia Nervosa Market, by Age Group
10.1. Adolescents
10.2. Adults
10.3. Children
11. Anorexia Nervosa Market, by End User
11.1. Hospitals
11.2. Specialized Clinics
11.3. Telehealth Providers
12. Anorexia Nervosa Market, by Region
12.1. Americas
12.1.1. North America
12.1.2. Latin America
12.2. Europe, Middle East & Africa
12.2.1. Europe
12.2.2. Middle East
12.2.3. Africa
12.3. Asia-Pacific
13. Anorexia Nervosa Market, by Group
13.1. ASEAN
13.2. GCC
13.3. European Union
13.4. BRICS
13.5. G7
13.6. NATO
14. Anorexia Nervosa Market, by Country
14.1. United States
14.2. Canada
14.3. Mexico
14.4. Brazil
14.5. United Kingdom
14.6. Germany
14.7. France
14.8. Russia
14.9. Italy
14.10. Spain
14.11. China
14.12. India
14.13. Japan
14.14. Australia
14.15. South Korea
15. United States Anorexia Nervosa Market
16. China Anorexia Nervosa Market
17. Competitive Landscape
17.1. Market Concentration Analysis, 2025
17.1.1. Concentration Ratio (CR)
17.1.2. Herfindahl Hirschman Index (HHI)
17.2. Recent Developments & Impact Analysis, 2025
17.3. Product Portfolio Analysis, 2025
17.4. Benchmarking Analysis, 2025
17.5. Acadia Healthcare Company, Inc.
17.6. Alkermes plc
17.7. Amgen Inc.
17.8. Biohaven Pharmaceuticals
17.9. Eating Recovery Center, LLC
17.10. Hologic, Inc.
17.11. Johnson & Johnson
17.12. Merck & Co., Inc.
17.13. Mindstrong Health
17.14. Monte Nido & Affiliates, LLC
17.15. Otsuka Pharmaceutical Co., Ltd.
17.16. Pfizer Inc.
17.17. Priory Group Ltd
17.18. PsychoGenics Inc.
17.19. Rogers Behavioral Health
17.20. Sanofi S.A.
17.21. Sumitomo Pharma America, Inc.
17.22. Takeda Pharmaceutical Company Limited
17.23. The Renfrew Center, Inc.
17.24. Tonix Pharmaceuticals Holding Corp.
17.25. Universal Health Services, Inc.
17.26. Walden Behavioral Care, Inc.
List of Figures
FIGURE 1. GLOBAL ANOREXIA NERVOSA MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL ANOREXIA NERVOSA MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL ANOREXIA NERVOSA MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. UNITED STATES ANOREXIA NERVOSA MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 12. CHINA ANOREXIA NERVOSA MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL ANOREXIA NERVOSA MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY DAY TREATMENT PROGRAM, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY DAY TREATMENT PROGRAM, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY DAY TREATMENT PROGRAM, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY INPATIENT HOSPITALIZATION, BY REGION, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY INPATIENT HOSPITALIZATION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY INPATIENT HOSPITALIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY RESIDENTIAL TREATMENT, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY RESIDENTIAL TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY RESIDENTIAL TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY NUTRITIONAL COUNSELING, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY NUTRITIONAL COUNSELING, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY NUTRITIONAL COUNSELING, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY ATYPICAL ANTIPSYCHOTICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY ATYPICAL ANTIPSYCHOTICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY ATYPICAL ANTIPSYCHOTICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY COGNITIVE BEHAVIORAL THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY COGNITIVE BEHAVIORAL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY COGNITIVE BEHAVIORAL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY FAMILY BASED THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY FAMILY BASED THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY FAMILY BASED THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY INTERPERSONAL THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY INTERPERSONAL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY INTERPERSONAL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY ADOLESCENTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY ADOLESCENTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY ADOLESCENTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY ADULTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY ADULTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY ADULTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY CHILDREN, BY REGION, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY CHILDREN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY CHILDREN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY SPECIALIZED CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY SPECIALIZED CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY SPECIALIZED CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY TELEHEALTH PROVIDERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY TELEHEALTH PROVIDERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY TELEHEALTH PROVIDERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 60. AMERICAS ANOREXIA NERVOSA MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 61. AMERICAS ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 62. AMERICAS ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 63. AMERICAS ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
TABLE 64. AMERICAS ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
TABLE 65. AMERICAS ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 66. AMERICAS ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 67. NORTH AMERICA ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 68. NORTH AMERICA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 69. NORTH AMERICA ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 70. NORTH AMERICA ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
TABLE 71. NORTH AMERICA ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
TABLE 72. NORTH AMERICA ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 73. NORTH AMERICA ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 74. LATIN AMERICA ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 75. LATIN AMERICA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 76. LATIN AMERICA ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 77. LATIN AMERICA ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
TABLE 78. LATIN AMERICA ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
TABLE 79. LATIN AMERICA ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 80. LATIN AMERICA ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 81. EUROPE, MIDDLE EAST & AFRICA ANOREXIA NERVOSA MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 82. EUROPE, MIDDLE EAST & AFRICA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 83. EUROPE, MIDDLE EAST & AFRICA ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 84. EUROPE, MIDDLE EAST & AFRICA ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
TABLE 85. EUROPE, MIDDLE EAST & AFRICA ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
TABLE 86. EUROPE, MIDDLE EAST & AFRICA ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 87. EUROPE, MIDDLE EAST & AFRICA ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 88. EUROPE ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 89. EUROPE ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 90. EUROPE ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 91. EUROPE ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
TABLE 92. EUROPE ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
TABLE 93. EUROPE ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 94. EUROPE ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 95. MIDDLE EAST ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 96. MIDDLE EAST ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 97. MIDDLE EAST ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 98. MIDDLE EAST ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
TABLE 99. MIDDLE EAST ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
TABLE 100. MIDDLE EAST ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 101. MIDDLE EAST ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 102. AFRICA ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 103. AFRICA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 104. AFRICA ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 105. AFRICA ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
TABLE 106. AFRICA ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
TABLE 107. AFRICA ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 108. AFRICA ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 109. ASIA-PACIFIC ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 110. ASIA-PACIFIC ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 111. ASIA-PACIFIC ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 112. ASIA-PACIFIC ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
TABLE 113. ASIA-PACIFIC ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
TABLE 114. ASIA-PACIFIC ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 115. ASIA-PACIFIC ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 116. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 117. ASEAN ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 118. ASEAN ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 119. ASEAN ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 120. ASEAN ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
TABLE 121. ASEAN ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
TABLE 122. ASEAN ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 123. ASEAN ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 124. GCC ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 125. GCC ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 126. GCC ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 127. GCC ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
TABLE 128. GCC ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
TABLE 129. GCC ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 130. GCC ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 131. EUROPEAN UNION ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 132. EUROPEAN UNION ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 133. EUROPEAN UNION ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 134. EUROPEAN UNION ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
TABLE 135. EUROPEAN UNION ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
TABLE 136. EUROPEAN UNION ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 137. EUROPEAN UNION ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 138. BRICS ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 139. BRICS ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 140. BRICS ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 141. BRICS ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
TABLE 142. BRICS ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
TABLE 143. BRICS ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 144. BRICS ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 145. G7 ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 146. G7 ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 147. G7 ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 148. G7 ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
TABLE 149. G7 ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
TABLE 150. G7 ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 151. G7 ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 152. NATO ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 153. NATO ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 154. NATO ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 155. NATO ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
TABLE 156. NATO ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
TABLE 157. NATO ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 158. NATO ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 159. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 160. UNITED STATES ANOREXIA NERVOSA MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 161. UNITED STATES ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 162. UNITED STATES ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 163. UNITED STATES ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
TABLE 164. UNITED STATES ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
TABLE 165. UNITED STATES ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 166. UNITED STATES ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 167. CHINA ANOREXIA NERVOSA MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 168. CHINA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 169. CHINA ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 170. CHINA ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
TABLE 171. CHINA ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
TABLE 172. CHINA ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 173. CHINA ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Anorexia Nervosa market report include:
  • Acadia Healthcare Company, Inc.
  • Alkermes plc
  • Amgen Inc.
  • Biohaven Pharmaceuticals
  • Eating Recovery Center, LLC
  • Hologic, Inc.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Mindstrong Health
  • Monte Nido & Affiliates, LLC
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Priory Group Ltd
  • PsychoGenics Inc.
  • Rogers Behavioral Health
  • Sanofi S.A.
  • Sumitomo Pharma America, Inc.
  • Takeda Pharmaceutical Company Limited
  • The Renfrew Center, Inc.
  • Tonix Pharmaceuticals Holding Corp.
  • Universal Health Services, Inc.
  • Walden Behavioral Care, Inc.